Stockscreener 앱 받기
15.75
12.02%
1.69
전일 마감가:
$14.06
열려 있는:
$14.79
하루 거래량:
971.99K
Relative Volume:
0.58
시가총액:
$345.09M
수익:
-
순이익/손실:
$-112.46M
주가수익비율:
-9.6037
EPS:
-1.64
순현금흐름:
$-99.89M
1주 성능:
+16.49%
1개월 성능:
-0.44%
6개월 성능:
-62.85%
1년 성능:
-42.10%
1일 변동 폭
$14.20
$15.80
1주일 범위
$13.00
$15.80
52주 변동 폭
$2.622
$65.80
보 바이오파마 Stock (VOR) Company Profile
명칭
Vor Biopharma Inc
전화
617-655-6580
주소
500 BOYLSTON STREET, BOSTON
VOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
15.75 | 308.06M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
보 바이오파마 Stock (VOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Citigroup | Buy |
| 2025-12-17 | 개시 | TD Cowen | Buy |
| 2025-12-09 | 개시 | JP Morgan | Overweight |
| 2025-11-25 | 재개 | Wedbush | Neutral |
| 2025-10-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | 업그레이드 | Stifel | Hold → Buy |
| 2025-06-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 개시 | Wedbush | Outperform |
| 2022-04-27 | 개시 | Goldman | Neutral |
| 2021-12-17 | 개시 | H.C. Wainwright | Buy |
| 2021-12-03 | 개시 | Robert W. Baird | Outperform |
| 2021-12-02 | 개시 | Oppenheimer | Outperform |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-03-03 | 개시 | Evercore ISI | Outperform |
| 2021-03-02 | 개시 | Goldman | Sell |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
보 바이오파마 주식(VOR)의 최신 뉴스
VOR: Telitacicept drives a global autoimmune strategy, backed by strong data, funding, and expert leadership - TradingView — Track All Markets
Quarterly Risk: How Vor Biopharma Inc stock valuations compare to rivals2025 Retail Activity & Weekly Top Performers Watchlists - Bộ Nội Vụ
Citigroup Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation - Nasdaq
Vor Biopharma (VOR) Receives New 'Buy' Rating From Citigroup | V - GuruFocus
Citigroup Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Citi Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
How Vor Biopharma Inc. stock responds to policy changes2025 EndofYear Setup & Growth Focused Investment Plans - ulpravda.ru
Will Vor Biopharma Inc. stock return to pre crisis levelsMarket Sentiment Report & Community Consensus Picks - ulpravda.ru
How Vor Biopharma Inc. stock valuations compare to rivals2025 Year in Review & High Accuracy Swing Entry Alerts - Улправда
Why Vor Biopharma Inc. stock remains a top recommendationTrade Volume Report & Stock Timing and Entry Methods - ulpravda.ru
Guidance Update: How Vor Biopharma Inc. stock responds to policy changes2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
Why Vor Biopharma Inc. stock is a must watch in 2025Market Rally & Stepwise Entry and Exit Trade Signals - ulpravda.ru
How Vor Biopharma Inc. stock benefits from global expansionMonthly Performance Summary & Start Small. End Wealthy. - bollywoodhelpline.com
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
What drives Vor Biopharma Inc stock priceInstitutional Buying Trends & Low Entry Cost Trading - earlytimes.in
Ariose Capital Management Ltd Invests $5.37 Million in Vor Biopharma Inc. $VOR - MarketBeat
Vor Biopharma Inc Stock Analysis and ForecastSell Signals and Alerts & Free High Yield Growth Strategies - earlytimes.in
Aug Macro: Will Vor Biopharma Inc stock outperform international peersFed Meeting & Verified Momentum Stock Watchlist - moha.gov.vn
Vor Biopharma CDO Departs, Transition Support Planned - TipRanks
Vor Biopharma Target of Unusually High Options Trading (NASDAQ:VOR) - MarketBeat
Portfolio Update: How Vor Biopharma Inc. stock benefits from global expansionTrade Risk Report & Fast Entry and Exit Trade Plans - moha.gov.vn
Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors - ts2.tech
Gap Down: Is Vor Biopharma Inc stock positioned well for digital economyJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - moha.gov.vn
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Moving Averages: How strong is Celsius Holdings Inc stock balance sheet2025 Short Interest & Community Verified Swing Trade Signals - moha.gov.vn
Vor Biopharma Stock (+7.4%): New Board Signals Institutional Backing - Trefis
Vor Biopharma Inc. (NASDAQ:VOR) Sees Large Growth in Short Interest - MarketBeat
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors - The Globe and Mail
Vor Biopharma adds two investment partners to board of directors By Investing.com - Investing.com Nigeria
Vor Biopharma Inc Announces Board Appointments - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to NASDAQ Biotechnology Index - marketscreener.com
VOR: JP Morgan Lowers Price Target While Maintaining Overweight Rating | VOR Stock News - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Why Vor Biopharma Inc. stock appeals to dividend seekersJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - ulpravda.ru
Vor Biopharma Signs Multiple Financing Agreements - TradingView — Track All Markets
Vor Biopharma (VOR) secures $150M private placement and adds two directors - Stock Titan
Technical Analysis: Will Vor Biopharma Inc. stock reach all time highs in 2025Earnings Performance Report & Accurate Technical Buy Alerts - Улправда
Vor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpoint - MSN
Vor Biopharma: Initiating Hold Rating On Durable Telitacicept MG Study Data - Seeking Alpha
Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential By Investing.com - Investing.com South Africa
VOR: TD Cowen Initiates Coverage with a 'Buy' Rating | VOR Stock News - GuruFocus
Vor Biopharma (NASDAQ:VOR) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Stocks to watch: Vor Biopharma sees RS rating jump to 89 - MSN
TD Cowen Initiates Vor Biopharma at Buy - marketscreener.com
Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential - Investing.com Australia
보 바이오파마 (VOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
보 바이오파마 주식 (VOR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 28 '25 |
Sale |
27.42 |
124,311 |
3,408,230 |
1,055,749 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 30 '25 |
Sale |
25.12 |
24,579 |
617,424 |
779,652 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 27 '25 |
Sale |
28.12 |
90,941 |
2,557,261 |
1,180,060 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 23 '25 |
Sale |
28.01 |
76,880 |
2,153,409 |
1,324,346 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 24 '25 |
Sale |
28.01 |
53,345 |
1,494,193 |
1,271,001 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 20 '25 |
Sale |
29.67 |
92,023 |
2,730,483 |
0 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 21 '25 |
Sale |
28.11 |
25,027 |
703,509 |
1,401,226 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 17 '25 |
Sale |
30.25 |
25,717 |
777,987 |
1,178,725 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 20 '25 |
Sale |
30.05 |
11,616 |
349,101 |
1,167,109 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 21 '25 |
Sale |
30.07 |
200 |
6,015 |
1,166,909 |
4.73%
0.92%
자본화:
|
볼륨(24시간):